- FROM THE EDITOR
The highest Impact Factor of Kardiologia Polska announced
in June 2021: we did it!
Anetta Undas1, 2
1Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland
2John Paul II Hospital, Kraków, Poland
Correspondence to:
Prof. Anetta Undas, MD, PhD,
Institute of Cardiology, Jagiellonian University Medical College,
Prądnicka 80,
31–202 Kraków, Poland,
phone: +48 12 614 30 04,
e-mail:
mmundas@cyf-kr.edu.pl
Copyright by the Author(s), 2021
Kardiol Pol. 2021;
79 (7–8): 723–724;
DOI: 10.33963/KP.a2021.0082
Received:
July 30, 2021
Revision accepted:
July 30, 2021
Published online:
August 25, 2021
On June 30, 2021, new Impact Factor (IF) values have been announced by Clarivate Analytics. As expected, the 2020 IF for Kardiologia Polska (Kardiol Pol, Polish Heart Journal) has exceeded not only 2.0, but also 3.0. Its exact value is 3.108. This is a recognition of the quality of the research published in our journal. The IF shows a previously underestimated potential of Polish cardiology, both the academic and non-academic settings, a growing number of cardiologists dealing with patients suffering from a wide spectrum of cardiac disorders and exploring novel pathophysiological mechanisms underlying cardiovascular diseases. I would like to thank you all — our authors, reviewers, and editorial board members — for your invaluable contribution to the journal’s success. The major contributors to the 2020 IF among all original and review articles published in Kardiol Pol, including 4 high-quality invited reviews from international experts, have been listed in
Table 1.
Table 1. Ten papers published in our journal in 2018 or 2019, which were most cited in 2020 and most contributed to the 2020 IF of 3.108 (derived from JCR 2021 published on June 30, 2021)
|
Title |
Authors |
Reference |
Citation count |
|
Oxidative stress and cardiovascular disease: new insights |
Pignatelli P, Menichelli D, Pastori D, et al. |
Volume: 76, Issue: 4, Pages: 713–722; Published: 2018 |
19 |
|
Hematological indices as predictors of atrial fibrillation following isolated coronary artery bypass grafting, valvular surgery, or combined procedures: a systematic review with meta-analysis |
Weymann A, Ali-Hasan-Al- |
Volume: 76, Issue: 1, Pages: 107–118, Published: 2018 |
13 |
|
Catheter ablation of atrial fibrillation: current status, techniques, outcomes, and challenges |
Hindricks G, Shamloo AS, Lenarczyk R, et al. |
Volume: 76, Issue: 12, Pages: 1680–1686; Published: 2018 |
13 |
|
Differences in knowledge among patients with atrial fibrillation receiving non-vitamin K antagonist oral anticoagulants and vitamin K antagonists |
Konieczynska M, Sobieraj E, Bryk A, et al. |
Volume: 76, Issue: 7, Pages: 1089–1096; Published: 2018 |
12 |
|
Safety and efficacy of ETC-1002 in hypercholesterolemic patients: a meta-analysis of randomized controlled trials |
Wang X, Luo S, Gan X, et al. |
Volume: 77 Issue: 2 Pages: 207–216; Published: 2019 |
11 |
|
How can we reverse bleeding in patients on direct oral anticoagulants? |
Crowther M, Cuker A |
Volume: 77, Issue: 1, Pages: 3–11; |
10 |
|
Fungal endocarditis: what do we know in 2019? |
Ammannaya GKK, Sripad N |
Volume: 77, Issue 7–8, Pages 670–673; Published: 2019 |
10 |
|
The usefulness of C-reactive protein for the prediction of post-infarct left ventricular systolic dysfunction and heart failure |
Świątkiewicz I, Taub PR |
Volume: 76, Issue 5, Pages 821–829; Published: 2018 |
9 |
|
Baseline and postoperative levels of C-reactive protein and interleukins as inflammatory predictors of atrial fibrillation following cardiac surgery: a systematic review and meta-analysis |
Weymann A, Sedaghat M, Baker WL, et al. |
Volume: 76, Issue 2, Pages 440–451; Published: 2018 |
9 |
|
Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis: one-year outcomes |
Bartuś K, Litwinowicz R, Kuśmierczyk M, et al. |
Volume: 76, Issue 3, Pages 618–624, Published: 2018 |
7 |
The scientists who most frequently cited the articles from Kardiol Pol in 2020 have also been provided in Table 2.
Table 2. Ten top citing authors
|
Authors |
Number of citing papers |
Number of citing papers from Kardiol Pol |
Number of citing papers from other journals |
|
Undas Anetta |
21 |
3 |
18 |
|
Lesiak Maciej |
15 |
11 |
4 |
|
Opolski Grzegorz |
12 |
5 |
7 |
|
Gąsior Mariusz |
12 |
7 |
5 |
|
Podolec Piotr |
11 |
4 |
7 |
|
Wojakowski Wojciech |
11 |
7 |
4 |
|
Kapelak Bogusław |
10 |
2 |
8 |
|
Grygier Marek |
10 |
5 |
5 |
|
Kopeć Grzegorz |
10 |
3 |
7 |
|
Grabowski Marcin |
10 |
5 |
5 |
Our top reviewers from 2020 whose insightful and timely reviews are essential in our editorial efforts and will contribute to the IF to be announced in 2022 and 2023 are listed in Table 3.
Table 3. Twelve top reviewers of 2020
|
Reviewer |
Number of completed reviews |
|
Farkowski Michal |
15 |
|
Dziewierz Artur |
14 |
|
Perek Bartłomiej |
14 |
|
Grygier Marek |
13 |
|
Kourtis Konstantinos |
12 |
|
Blicharz Jarosław |
11 |
|
Iwańczyk Sylwia |
11 |
|
Wojakowski Wojciech |
11 |
|
Araszkiewicz Aleksander |
10 |
|
Świerżyńska Ewa |
10 |
|
Matusik Paweł |
10 |
|
Dąbrowski Rafał |
10 |
Their work is greatly appreciated and deserves our recognition.
A journal’s IF, a basic measure of the quality of journals, is determined by dividing all citations to this journal within the particular year (2020 in this case) by the number of citable articles encompassing original articles and reviews published in this journal during the two precedent years (in 2018 and 2019 in this case, the years in which most articles were published based on the decision of the current Editors). Indeed, the current IF of 3.108 proves how well our team has selected and disseminated the content of Kardiol Pol. Since the latest IF markedly influences an author’s choice of where to publish their manuscripts, we hope that more and more good papers will be submitted and finally published in Kardiol Pol. To maintain our standing and ensure further growth, we promise to the cardiology community in Poland that the articles in the years to come will be as good as they possibly can be. Excellence, innovative hypotheses, and sound methodology are the keys to successful submissions to Kardiol Pol. This is the source of success. We firmly believe that we are achieving our aims beyond the current IF and our present strategy guarantees that the journal’s reputation and prestige we have increased are solid.
Our next goal is that the 2021 IF of Kardiol Pol will surpass the current value. We can achieve more, and we will do so. We hope that the joint efforts of authors, reviewers, and editors, supported by the publisher’s expertise and experience, will lead to the continued growth of our journal and the promotion of high-quality research in the field of cardiology.
Article information
Conflict of interest: None declared.
Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.
How to cite: Undas A. The highest Impact Factor for Kardiol Pol announced in June 2021: we did it! Kardiol Pol. 2021; 79(7–8): 723–724, doi: 10.33963/KP.a2021.0082.
Comment: Several opinion leaders from the Polish Cardiac Society have supported my team in our hard work to enhance the standing of Kardiologia Polska. I do appreciate stimulating remarks and trust in my ability to lead the editorial team to achieve the Impact Factor higher than 2.5 within 3 years, presented by Prof. Piotr Pruszczyk during a session sponsored by Boehringer Ingelheim at the Spring Conference of the Polish Cardiac Society in May 2018. As a proof, a funny slide from this event is presented above (with permission)
